The proposed additional indication for ZERBAXA is based on results of the pivotal Phase 3 ASPECT-NP trial that evaluated the efficacy and safety of ZERBAXA at a 3g dose for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results